CN115023435B - 免疫治疗化合物和方法 - Google Patents

免疫治疗化合物和方法

Info

Publication number
CN115023435B
CN115023435B CN202080079445.7A CN202080079445A CN115023435B CN 115023435 B CN115023435 B CN 115023435B CN 202080079445 A CN202080079445 A CN 202080079445A CN 115023435 B CN115023435 B CN 115023435B
Authority
CN
China
Prior art keywords
seq
amino acid
cells
compound
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080079445.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN115023435A (zh
Inventor
D·A·瓦列拉
J·S·米勒
M·菲里西斯
M·施勒德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GT Biopharma Inc
University of Minnesota System
Original Assignee
GT Biopharma Inc
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GT Biopharma Inc, University of Minnesota System filed Critical GT Biopharma Inc
Publication of CN115023435A publication Critical patent/CN115023435A/zh
Application granted granted Critical
Publication of CN115023435B publication Critical patent/CN115023435B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080079445.7A 2019-09-16 2020-09-15 免疫治疗化合物和方法 Active CN115023435B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901198P 2019-09-16 2019-09-16
US62/901198 2019-09-16
PCT/US2020/050851 WO2021055342A1 (en) 2019-09-16 2020-09-15 Immunotherapy compounds and methods

Publications (2)

Publication Number Publication Date
CN115023435A CN115023435A (zh) 2022-09-06
CN115023435B true CN115023435B (zh) 2026-03-27

Family

ID=74883667

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080079445.7A Active CN115023435B (zh) 2019-09-16 2020-09-15 免疫治疗化合物和方法

Country Status (10)

Country Link
US (1) US20220324972A1 (https=)
EP (1) EP4031565A4 (https=)
JP (2) JP7773152B2 (https=)
KR (1) KR20220087441A (https=)
CN (1) CN115023435B (https=)
AU (1) AU2020350524A1 (https=)
BR (1) BR112022004712A2 (https=)
CA (1) CA3154158A1 (https=)
IL (1) IL291343A (https=)
WO (1) WO2021055342A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
KR20240067088A (ko) * 2021-09-16 2024-05-16 지티 바이오파마, 인크. 융합 단백질을 표적으로 하는 pd-l1 및 이의 사용 방법
WO2025136820A1 (en) * 2023-12-18 2025-06-26 Regents Of The University Of Minnesota Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697736A (zh) * 2015-10-06 2018-10-23 明尼苏达大学董事会 治疗性组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN01299A (https=) * 2012-07-23 2015-07-03 Zymeworks Inc
CA2924398A1 (en) * 2013-11-05 2015-05-14 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
KR102762243B1 (ko) * 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
EP3322735A4 (en) * 2015-07-15 2019-03-13 Zymeworks Inc. ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697736A (zh) * 2015-10-06 2018-10-23 明尼苏达大学董事会 治疗性组合物和方法

Also Published As

Publication number Publication date
BR112022004712A2 (pt) 2022-06-14
JP2022548145A (ja) 2022-11-16
KR20220087441A (ko) 2022-06-24
JP7773152B2 (ja) 2025-11-19
CN115023435A (zh) 2022-09-06
CA3154158A1 (en) 2021-03-25
AU2020350524A1 (en) 2022-04-21
WO2021055342A1 (en) 2021-03-25
EP4031565A1 (en) 2022-07-27
EP4031565A4 (en) 2023-10-25
US20220324972A1 (en) 2022-10-13
IL291343A (en) 2022-05-01
JP2026021424A (ja) 2026-02-10

Similar Documents

Publication Publication Date Title
CN107849148B (zh) 三特异性结合蛋白质及使用方法
CN105121474B (zh) 融合免疫调节蛋白及其制备方法
EP4019550A1 (en) Anti-pd-l1 single domain antibodies
KR102897353B1 (ko) Nk 관여 분자 및 이의 사용 방법
CN115023435B (zh) 免疫治疗化合物和方法
CA3183711A1 (en) B7h3-targeting proteins and methods of use thereof
KR20230126713A (ko) Cea6 결합 분자 및 이의 사용
AU2017214685B2 (en) EGFL6 specific monoclonal antibodies and methods of their use
CN109627340B (zh) Cd3和prlr双特异性抗体及其构建与应用
KR20230126714A (ko) 메소텔린 결합 분자 및 이의 사용
CN114929745B (zh) Clec12a抗体片段序列和方法
EP4435006A1 (en) Bispecific antibody and use thereof
US12269887B2 (en) Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using
EP3356394A1 (en) Deimmunized therapeutic compositions and methods
WO2017138471A1 (ja) 抗イヌｃｄ７０モノクローナル抗体
US20240317831A1 (en) Nk cell engager molecules and methods of use
CN115785269B (zh) 抗pd-l1的抗体及其应用
WO2025136820A1 (en) Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use
WO2025256479A1 (zh) 一种融合蛋白及其用途
KR20230125809A (ko) Fap 결합 분자 및 이의 사용
JP2026074003A (ja) Ｂ７ｈ３標的タンパク質及びその使用方法
HK40117294A (en) Bispecific antibody and use thereof
EA042513B1 (ru) Psma-нацеленные триспецифические белки и способы их применения
HK1263031A1 (zh) 去免疫的治疗性组合物和方法
HK1217343B (zh) 融合免疫调节蛋白及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant